JP3807782B2 - Hyaluronidase inhibitor - Google Patents
Hyaluronidase inhibitor Download PDFInfo
- Publication number
- JP3807782B2 JP3807782B2 JP15446896A JP15446896A JP3807782B2 JP 3807782 B2 JP3807782 B2 JP 3807782B2 JP 15446896 A JP15446896 A JP 15446896A JP 15446896 A JP15446896 A JP 15446896A JP 3807782 B2 JP3807782 B2 JP 3807782B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- genus
- hyaluronidase
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940122393 Hyaluronidase inhibitor Drugs 0.000 title claims description 13
- 239000000284 extract Substances 0.000 claims description 40
- 241001474374 Blennius Species 0.000 claims description 33
- 241000195628 Chlorophyta Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 22
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 22
- 229960002773 hyaluronidase Drugs 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 18
- -1 pH adjusters Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 229920002674 hyaluronan Polymers 0.000 description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 11
- 229960003160 hyaluronic acid Drugs 0.000 description 11
- 239000006210 lotion Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241001147493 Iridaea Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- 241000199919 Phaeophyceae Species 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241001260563 Lessonia nigrescens Species 0.000 description 4
- 241001491705 Macrocystis pyrifera Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 241000673611 Pterocladiella tenuis Species 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001467355 Gigartina Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001512709 Lessonia <stramenopiles> Species 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 241000206608 Pyropia tenera Species 0.000 description 3
- 241000206572 Rhodophyta Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001392689 Ecklonia maxima Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241001491708 Macrocystis Species 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000206613 Pyropia yezoensis Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- 241001442124 Analipus japonicus Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241001083548 Anemone Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000196211 Bryopsis plumosa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001339217 Caulerpa lentillifera Species 0.000 description 1
- 241001168955 Ceramium boydenii Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000980780 Cladosiphon okamuranus Species 0.000 description 1
- 241000196222 Codium fragile Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000219428 Fagaceae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000691324 Gloiopeltis tenax Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001147491 Mazzaella cornucopiae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-BKJPEWSUSA-N N-acetyl-D-hexosamine Chemical compound CC(=O)NC1C(O)O[C@H](CO)C(O)C1O OVRNDRQMDRJTHS-BKJPEWSUSA-N 0.000 description 1
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000206754 Palmaria palmata Species 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- ZCLVNIZJEKLGFA-UHFFFAOYSA-H bis(4,5-dioxo-1,3,2-dioxalumolan-2-yl) oxalate Chemical compound [Al+3].[Al+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O ZCLVNIZJEKLGFA-UHFFFAOYSA-H 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940071120 dehydroacetate Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- YVIGPQSYEAOLAD-UHFFFAOYSA-L disodium;dodecyl phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O YVIGPQSYEAOLAD-UHFFFAOYSA-L 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- WYVGZXIHGGQSQN-UHFFFAOYSA-N hexadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCCCCC(O)=O WYVGZXIHGGQSQN-UHFFFAOYSA-N 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- MQOCIYICOGDBSG-UHFFFAOYSA-M potassium;hexadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCC([O-])=O MQOCIYICOGDBSG-UHFFFAOYSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 239000001651 pyrus cydonia seed extract Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】
【産業上の利用分野】
本発明は、優れたヒアルロニダーゼ阻害活性を有する、極めて安全性の高い海藻抽出物よりなるヒアルロニダーゼ阻害剤に関する。
【0002】
【従来の技術】
ヒアルロニダーゼは、ヒアルロン酸の加水分解酵素であり、皮膚のほか動物組織に広く分布している。本酵素の基質となるヒアルロン酸は、皮膚、靭帯、関節液、眼の硝子体などの組織に多く存在するムコ多糖の一種であり、例えば、皮膚においては、細胞の保護、栄養の運搬、組織水分の保持、柔軟性の維持等に、また関節液として組織構造、機能の維持および潤滑性の保持等に、重要な役割を果たしている。
【0003】
皮膚や関節における生体ヒアルロン酸量は、老化または病的状態により減少することが知られており、その結果、皮膚の乾燥、肌荒れ、ハリ、弾力性の低下、シミ、シワの増加、あるいは関節の湿潤性悪化による関節痛等を引き起こす。
このような状態に対して、ヒアルロニダーゼ阻害剤は、ヒアルロン酸の分解を抑制することにより生体ヒアルロン酸量の維持に寄与すると考えられている。
また、最近では、ヒアルロン酸を配合した化粧料の皮膚への塗布や関節へのヒアルロン酸の注入等の措置がとられているが、ヒアルロニダーゼ阻害剤は、これら外因性ヒアルロン酸の安定化にも利用することができる。
【0004】
さらに、ヒアルロニダーゼは、炎症時に活性化され、結合組織のマトリックスを破壊し、炎症系の細胞の組織への浸潤、血管の透過性を亢進すること、I型アレルギーにおける肥満細胞からのヒスタミン遊離の過程に介在している可能性が高いことなどが知られている。
従って、ヒアルロニダーゼ阻害活性は、生体中のヒアルロン酸レベルの維持に関与するだけでなく、抗炎症、抗アレルギー活性とも高い相関を示す。実際、これまでに開発された抗炎症剤、抗アレルギー剤であるインドメタシン、アスピリン、クロモグリク酸ナトリウム、トラニラストなど多くにヒアルロニダーゼ阻害活性が認められている。
【0005】
以上のようなことから、優れたヒアルロニダーゼ阻害活性を有し、かつ皮膚等の人体への適用に際し、高い安全性をもったヒアルロニダーゼ阻害剤の開発が期待されている。
【0006】
【発明が解決しようとする課題】
本発明は、優れたヒアルロニダーゼ阻害活性を有し、しかも安全性に優れたヒアルロニダーゼ阻害剤を提供することを目的とする。
【0007】
【課題を解決するための手段】
本発明者らは、上記課題を解決すべく、種々の天然物、特に植物抽出物を対象として検討を行った。
既に陸上植物については、飲用に供されている茶から抽出される茶ポリフェノール類(特開平6−9391号)、生薬又は飲食物として使用されているチンピ、キジツ、羅漢果の抽出物(特開平6−80576号)、ブナ科の植物であるウラジロガシ抽出物(特開平6−239757号)、カシューナッツ殻油(特開平6−329526号)、ウルシ科植物抽出物(特開平7−10765号)等からヒアルロニダーゼ阻害活性等をもつ物質が見い出されているが、本発明者らは、新たなヒアルロニダーゼ阻害剤を開発すべく、鋭意スクリーニングを行った結果、以下に示す海藻類の抽出物に目的のヒアルロニダーゼ阻害活性を見い出し、本発明を完成するに至ったのである。
【0008】
すなわち、本発明のヒアルロニダーゼ阻害剤は、緑藻類のハネモ属、イワヅタ属、ミル属、褐藻類のマツモ属、オキナワモズク属、モズク属、レッソニア属、マクロシスティス属、ヒバマタ属、ダービリア属、紅藻類のアマノリ属、ヒラクサ属、オバクサ属、フノリ属、スギノリ属、イリダエ属(Iridaea属)、ツノマタ属、ダルス属、イギス属に属する海藻の抽出物を有効成分として含有することを特徴とする。
【0009】
【作用】
本発明の海藻抽出物が、皮膚等に対して優れた老化防止効果等を発揮する機構については、抽出物中に含まれるヒアルロニダーゼ阻害活性物質が、皮膚細胞におけるヒアルロン酸の分解を抑制、そのレベルを維持することにより、皮膚の保湿性、柔軟性、弾力性の低下を抑え、顕著な皮膚老化防止効果等を示すものと推測される。
また、その優れたヒアルロニダーゼ阻害活性により、ヒアルロニダーゼに起因する炎症やアレルギーの予防、治療に有効となる。
【0010】
以下に、本発明の内容を詳細に説明する。
本発明に用いられる海藻としては、例えば、緑藻類の、ハネモ属ではハネモ(Bryopsis plumosa)、イワヅタ属では、クビレヅタ(Caulerpa lentillifera)、ミル属ではミル(Codium fragile)、褐藻類の、マツモ属ではマツモ(Analipus japonicus)、オキナワモズク属ではオキナワモズク(Cladosiphon okamuranus)、モズク属ではモズク(Nemacystis decipiens)、レッソニア属ではLessonia nigrescens 、マクロシスティス属ではジャイアントケルプ(Macrocystis pyrifera)、ヒバマタ属ではヒバマタ(Fucus evanescens)、ダービリア属ではDurvillea antarctica、紅藻類の、アマノリ属ではアサクサノリ(Porphyra tenera)、スサビノリ(Porphyra yezoensis)、ヒラクサ属ではヒラクサ(Beckerella subcostata)、オバクサ属ではPterocladia tenuis、フノリ属ではフクロフノリ(Gloiopeltis furcata)、マフノリ(Gloiopeltis tenax)、スギノリ属ではGigartina chamissoi、イリダエ属(Iridaea属)ではIridaea pulchra、エゾツノマタ(別名クロハギンナンソウ)(Iridaea cornucopiae)、ツノマタ属ではトチャカ(Chondrus crispus)ツノマタ(Chondrus occellatus)、ダルス属ではダルス(Rhodymenia palmata)、イギス属ではアミクサ(Ceramium boydenii)などを挙げることができる。
【0011】
本発明物質を抽出する方法は、特に制限はなく、通常の抽出法が採用され、水、親水性有機溶媒、その他の有機溶媒等よりなる群から選ばれる単独あるいは2種以上の任意の混合溶剤を使用して海藻から抽出される。
有機溶媒としては、例えば、メタノール、エタノール、イソプロパノール、n−ブタノール、1,3−ブチレングリコール、プロピレングリコール、酢酸エチル、アセトン、メチルエチルケトン、アセトニトリル、ジメチルスルホキシド、ジメチルホルムアミド、クロロホルム、n−ヘキサン、ベンゼン等が挙げられる。
これらの中でも、特に、水または水とメタノール、エタノール、イソプロパノール等の低級アルコールとの混合物を用いて抽出することが好ましい。この場合の水と低級アルコールの比率は、水/低級アルコールが100/0〜30/70(V/V、体積比)であることが好ましい。
海藻原体と抽出溶媒との比率は、海藻原体(乾燥物)/溶媒比が1/50〜1/2の範囲が好ましい。
その他の抽出条件としては、抽出温度は特に制限はないが、好ましくは5〜80℃の範囲で、1〜24時間、撹拌しながら行うのが好ましい。抽出pHは、極端な酸性、極端なアルカリ性に傾かなければ、特に制限はない。
【0012】
この抽出液は、そのまま用いても、あるいは希釈液としたり、濃縮エキスとしてもよく、また凍結乾燥などにより乾燥粉末物としたり、ペースト状に調製してもよい。
乾燥粉末に調製した場合には、水または水を含むメタノール、エタノール、イソプロパノール等の低級アルコールに予め溶解して用いるか、あるいは後述の水を含む外用組成物中で可溶化して用いるのが好ましい。
【0013】
本発明のヒアルロニダーゼ阻害剤の剤型としては、例えば、錠剤、カプセル剤、散剤、内服液、細粒剤等の内服剤とすることができ、また、リニメント剤、スプレー剤、ローション剤、軟膏等の外皮用とすることができる。
皮膚外用剤として用いる場合には、必須成分である海藻抽出物を任意の濃度で配合できるが、通常、各種皮膚外用剤中に0.01〜30重量%(以下、単に「%」という。)、好ましくは0.1〜10%配合させるのがよい。
【0014】
本発明の必須成分である海藻抽出物を配合した皮膚外用剤には、上記必須成分の他に、通常外用剤に用いられる原料、例えば、界面活性剤、油分、アルコール類、保湿剤、増粘剤、防腐剤、酸化防止剤、キレート剤、pH調整剤、香料、色素、紫外線吸収・散乱剤、ビタミン類、アミノ酸類、水等を配合することができる。
【0015】
具体的には、界面活性剤としては、親油型グリセリンモノステアレート、自己乳化型グリセリンモノステアレート、ポリグリセリンモノステアレート、ソルビタンモノオレート、ポリエチレングリコールモノステアレート、ポリオキシエチレンソルビタンモノオレート、ポリオキシエチレンセチルエーテル、ポリオキシエチレン化ステロール、ポリオキシエチレン化ラノリン、ポリオキシエチレン化蜜ロウ、ポリオキシエチレン硬化ヒマシ油等のノニオン界面活性剤、ステアリン酸ナトリウム、パルミチン酸カリウム、セチル硫酸ナトリウム、ラウリルリン酸ナトリウム、パルミチン酸トリエタノールアミン、ポリオキシエチレンラウリルリン酸ナトリウム、N−アシルグルタミン酸ナトリウム等のアニオン界面活性剤、塩化ステアリルジメチルベンジルアンモニウム、塩化ステアリルトリメチルアンモニウム等のカチオン界面活性剤、塩酸アルキルアミノエチルグリシン液、レシチン等の両性界面活性剤等を例示することができる。
【0016】
油分としては、ヒマシ油、オリーブ油、カカオ油、椿油、ヤシ油、木ロウ、ホホバ油、グレープシード油、アボガド油等の植物油脂類、ミンク油、卵黄油等の動物油脂類、蜜ロウ、鯨ロウ、ラノリン、カルナウバロウ、キャンデリラロウ等のロウ類、流動パラフィン、スクワラン、マイクロクリスタリンワックス、セレシンワックス、パラフィンワックス、ワセリン等の炭化水素類、ラウリン酸、ミリスチン酸、ステアリン酸、オレイン酸、イソステアリン酸、ベヘニン酸等の天然および合成脂肪酸類、セタノール、ステアリルアルコール、ヘキシルデカノール、オクチルドデカノール、ラウリルアルコール等の天然および合成高級アルコール類、ミリスチン酸イソプロピル、パルミチン酸イソプロピル、ミリスチン酸オクチルドデシル、オレイン酸オクチルドデシル、コレステロールオレート等のエステル類等を例示することができる。
【0017】
保湿剤としては、グリセリン、プロピレングリコール、1,3−ブチレングリコール、ソルビトール、ポリグリセリン、ポリエチレングリコール、ジプロピレングリコール等の多価アルコール類、アミノ酸、乳酸ナトリウム、ピロリドンカルボン酸ナトリウム等のNMF成分、ヒアルロン酸、コラーゲン、ムコ多糖類、コンドロイチン硫酸等の水溶性高分子物質等を例示することができる。
【0018】
増粘剤としては、アルギン酸ナトリウム、キサンタンガム、硅酸アルミニウム、マルメロ種子抽出物、トラガントガム、デンプン等の天然高分子物質、メチルセルロース、ヒドロキシエチルセルロース、カルボキシメチルセルロース、可溶性デンプン、カチオン化セルロース等の半合成高分子物質、カルボキシビニルポリマー、ポリビニルアルコール等の合成高分子物質等を例示することができる。
【0019】
防腐剤としては、安息香酸塩、サリチル酸塩、ソルビン酸塩、デヒドロ酢酸塩、パラオキシ安息香酸エステル、2,4,4’−トリクロロ−2’−ヒドロキシジフェニルエーテル、3,4,4’−トリクロロカルバニリド、塩化ベンザルコニウム、ヒノキチオール、レゾルシン、エタノール等を例示することができる。
【0020】
酸化防止剤としては、ジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、没食子酸プロピル、アスコルビン酸等を、キレート剤としては、エデト酸二ナトリウム、エチレンジアミン四酢酸塩、ピロリン酸塩、ヘキサメタリン酸塩、クエン酸、酒石酸、グルコン酸等を、pH調整剤としては、水酸化ナトリウム、トリエタノールアミン、クエン酸、クエン酸ナトリウム、ホウ酸、ホウ砂、リン酸水素カリウム等をそれぞれ例示することができる。
【0021】
紫外線吸収・散乱剤としては、2−ヒドロキシ−4−メトキシベンゾフェノン、オクチルジメチルパラアミノベンゾエート、エチルヘキシルパラメトキシサイナメート、酸化チタン、カオリン、タルク等を例示することができる。
ビタミン類としては、ビタミンA、ビタミンB、ビタミンC、ビタミンD、ビタミンE、ビタミンF、ビタミンK、ビタミンP、ビタミンU、カルニチン、フェルラ酸、γ−オリザノール、α−リポ酸、オロット酸およびそれらの誘導体等を例示することができる。
アミノ酸類としては、グリシン、アラニン、バリン、ロイシン、イソロイシン、セリン、トレオニン、フェニルアラニン、チロシン、トリプトファン、シスチン、システイン、メチオニン、プロリン、ヒドロキシプロリン、アスパラギン酸、グルタミン酸、アルギニン、ヒスチジン、リジンおよびそれらの誘導体等を例示することができる。
【0022】
なお、任意成分は、これらに限定されるものではない。上記必須成分と任意成分を適当に配合することにより、例えば、本発明の海藻抽出物0.01〜30%、任意成分として油分0〜80%、界面活性剤0〜12%、保湿剤1〜15%、精製水バランス、防腐剤微量を含有する皮膚外用剤を提供することができる。具体的には、クリーム、乳液、化粧水、美容液、パック剤、アンダーメークアップ、ファンデーション、ゼリー剤、軟膏等の製品形態として用いることができる。
【0023】
本発明のヒアルロニダーゼ阻害剤を皮膚化粧料として用いる場合の具体例を示すと以下の(1)〜(4)の通りである。
(1) 皮膚用クリームの場合
本発明の海藻抽出物0.1〜10%、油分20〜70%、界面活性剤2〜7%、保湿剤1〜10%、精製水バランス、防腐剤微量、香料微量を含有する皮膚用クリーム。
【0024】
(2) 乳液の場合
本発明の海藻抽出物0.1〜10%、油分10〜40%、アルコール類0〜15%、界面活性剤1〜5%、保湿剤1〜10%、増粘剤0〜2%、精製水バランス、防腐剤微量、香料微量を含有する乳液。
【0025】
(3) 化粧水、美容液の場合
本発明の海藻抽出物0.1〜10%、アルコール類5〜20%、界面活性剤0〜2%、保湿剤2〜8%、増粘剤0〜2%、酸化防止剤0〜0.5%、キレート剤0〜0.1%、pH調整剤0〜0.2%、精製水バランス、防腐剤微量、色素0〜微量、香料微量を含有する化粧水、美容液。
【0026】
(4) パック剤の場合
本発明の海藻抽出物0.1〜10%、アルコール類2〜10%、保湿剤2〜10%、無機粉体0〜20%、造膜剤10〜20%、精製水バランス、防腐剤微量、香料微量を含有するパック剤。
【0027】
【実施例】
次に、実施例、試験例等により本発明を具体的に説明するが、本発明は以下の実施例に限定されるものではない。
【0028】
製造例(海藻抽出物の製造)
マツモの乾燥物100gを20倍量の水にて3時間撹拌し、その上澄みを濃縮および凍結乾燥することにより、マツモ抽出物16gを得た。また、同様にして、マツモ以外の海藻、すなわち、緑藻類のハネモ、クビレヅタ、ミル、ホソジュズモ、褐藻類のオキナワモズク、モズク、Ecklonia maxima、ジャイアントケルプ、Lessonia nigrescens 、ヒバマタ、Durvillea antarctica、シオミドロ、紅藻類のオゴノリ、アサクサノリ、スサビノリ、ヒラクサ、Pterocladia tenuis、フクロフノリ、マフノリ、Gigartina chamissoi、Iridaea pulchra、エゾツノマタ、トチャカ、ツノマタ、ダルス、カギノリ、アミクサについて、夫々の抽出物を得た。
さらに、他の溶媒、すなわち、メタノール、エタノール、イソプロパノール、n−ブタノール、1,3−ブチレングリコール、プロピレングリコール、酢酸エチル、アセトン、メチルエチルケトン、アセトニトリル、ジメチルスルホキシド、ジメチルホルムアミド、クロロホルム、n−ヘキサン、ベンゼンについても、上記水と同様の方法で上記夫々の海藻類から抽出物を得た。
【0029】
試験例1(ヒアルロニダーゼ阻害活性試験)
上記製造例で得た夫々の海藻抽出物(エキス試料)のヒアルロニダーゼ阻害活性の測定は、以下の方法で行った。
酵素(type IV−S from Bovine testis,SIGMA社製)溶液100μl(1,580unit/ml)に上記製造例で得た夫々の海藻抽出エキス試料200μlを加えて、37℃で20分間放置した。次に、酵素活性化剤(Compound 48/80,SIGMA社製)溶液(0.1mg/ml)200μlを加え、37℃で20分間放置した後、基質であるヒアルロン酸カリウム(from rooster comb,和光純薬社製)溶液(0.4mg/ml)500μlを入れ、37℃で40分間放置した。
次いで、0.4N水酸化ナトリウム溶液200μlを加えて反応を停止させた後、Morgan-Elson法の変法(J. Biol. Chem.,217,959(1955))で生成したN−アセチルヘキソサミン量を吸光度OD585nmから求めた。
また、酵素反応には0.1mM 酢酸緩衝液(pH3.5)を用い、ヒアルロニダーゼ阻害活性は次式より求められる阻害率で算出した。
【0030】
【数1】
【0031】
上記製造例で得た夫々の海藻類の水抽出物(エキス試料)について、種々試料濃度での阻害率から50%阻害濃度(IC50)を算出した結果を下記表1に示す。数値が低い程、ヒアルロニダーゼ阻害活性が高いことを示す。
【0032】
【表1】
【0033】
(表1の考察)
上記表1に示した結果から明らかなように、本発明の海藻抽出物、すなわち、緑藻類のハネモ、クビレヅタ、ミル、褐藻類のマツモ、オキナワモズク、モズク、Ecklonia maxima、ジャイアントケルプ、Lessonia nigrescens 、ヒバマタ、Durvillea antarctica、紅藻類のアサクサノリ、スサビノリ、ヒラクサ、Pterocladia tenuis、フクロフノリ、マフノリ、Gigartina chamissoi、Iridaea pulchra、エゾツノマタ、トチャカ、ツノマタ、ダルス、アミクサの各抽出物は、ヒアルロニダーゼ阻害活性が知られているクロモグリク酸ナトリウム(対照)に匹敵する非常に高いヒアルロニダーゼ阻害活性を示すものが多く認められた。また、他の抽出溶媒から得られた抽出物も、水抽出物とほぼ同様の結果を示した。
特に、レッソニア属のLessonia nigrescens 、ダービリア属のDurvillea antarctica、フノリ属のマフノリ、Iridaea属のIridaea pulchra、エゾツノマタは、ヒアルロニダーゼ阻害活性が著しく高いことが判明した。
これに対し、同じ海藻抽出物であっても、本発明の範囲外となる海藻抽出物、すなわち、緑藻類のジュズモ属のホソジュズモ、褐藻類のシオミドロ属のシオミドロ、紅藻類のオゴノリ属のオゴノリ、カギノリ属のカギノリの夫々の抽出物は、ヒアルロニダーゼ阻害活性を示さなかった。
【0034】
実施例1、比較例1(クリームの製造)
下記表2に示す成分1〜7および8〜11を別々に混合溶解した後、成分8〜11の溶液を撹拌しながら、ここに成分1〜7の溶液を添加し乳化させた後、冷却しながら途中で成分12を加えて室温まで冷却し、下記表2に示すクリームを調製した。
なお、表中の数字は、配合量(重量%)を示し、POE(20)は、ポリオキシエチレンとその付加モル数を示す(以下の実施例等においても同様)。また、比較例1は、成分8の本発明の海藻抽出物を配合しないでクリームを調製した場合である(以下の比較例2〜4においても海藻抽出物を配合しないで調製したものである)。
【0035】
【表2】
【0036】
実施例2、比較例2(化粧水の製造)
下記表3に示す成分1〜6を順次成分7に加えて溶解し、さらに成分8を加え下記表3に示す化粧水を調製した。
【0037】
【表3】
【0038】
実施例3、比較例3(美容液の製造)
下記表4に示す成分1〜4と成分5〜9を別々に溶解後、混合して美容液を調製した。
【0039】
【表4】
【0040】
実施例4、比較例4(乳液の製造)
下記表5に示す成分1〜7を70℃で加熱溶解した。一方、成分8〜13を70℃で加熱溶解し、前記油脂溶液(成分1〜7)を添加し、乳化させた後、冷却しながら、途中で成分14を加えて室温まで冷却し、下記表5に示す乳液を調製した。
【0041】
【表5】
【0042】
試験例2(使用テスト評価結果)
上記製造例で得た各海藻の水抽出物を含む上記実施例1〜4及び比較例1〜4のクリーム、化粧水、美容液、乳液の有効性を下記の使用テストにより評価した。
(使用テスト)
女性(30〜50才)5名づつに、1日2回(朝と夜)、連続3カ月間実施例1〜4と比較例1〜4をハーフ・フェイス法で左右顔面に別々に使用させた後、小皺(A)および質〔艶(B)、潤い(C)〕についてアンケート調査を行った。
アンケート調査は、実施例(本発明品)が良い場合には○(改善効果あり)、実施例(本発明品)と比較例が変わらない場合には△、比較例が良い場合には×(改善効果なし)とした。
これらの使用テストの結果を下記表6に示す。
【0043】
【表6】
【0044】
(表6の考察)
上記表6に示す結果から明らかなように、本発明範囲の海藻の抽出物を配合した製剤(実施例)〔クリーム、化粧水、美容液、乳液〕は、小皺(A)、艶(B)、潤い(C)の改善効果が認められた。この効果は、海藻抽出物中に含まれるヒアルロニダーゼ阻害活性物質が、皮膚細胞におけるヒアルロン酸の分解を抑制、そのレベルを維持することにより、皮膚の保湿性、柔軟性、弾力性の低下を抑え、顕著な皮膚細胞の賦活化及び皮膚老化防止効果等を図り、皺や肌荒れの発生を予防し、滑らかでしっとりとした若々しい肌を与えたものと推測される。
一方、同じ海藻抽出物であっても、本発明範囲外となる海藻の抽出物、すなわち、緑藻類のジュズモ属のホソジュズモ、褐藻類のシオミドロ属のシオミドロ、紅藻類のオゴノリ属のオゴノリ、カギノリ属のカギノリの夫々の抽出物を配合した製剤(比較例)〔クリーム、化粧水、美容液、乳液〕は、小皺(A)、艶(B)、潤い(C)とも改善効果は認められなかった。
【0045】
【発明の効果】
本発明によれば、ヒアルロン酸分解抑制作用により、皮膚細胞の賦活化、皮膚の老化防止が図られ、皺や肌荒れの発生を予防、滑らかでしっとりとした若々しい肌を与える効果が得られ、これを配合することにより、安全性の高い皮膚外用剤等に好適なヒアルロニダーゼ阻害剤が提供される。
また、本発明のヒアルロニダーゼ阻害剤は、関節の湿潤性を保ち、関節の治療剤等としても利用でき、また、抗炎症、抗アレルギー剤としても有用である。
さらに、本発明のヒアルロニダーゼ阻害剤は、古くから食用等に用いられる海藻類から抽出されるものであるため、人体への安全性が極めて高く、しかも、優れたヒアルロニダーゼ阻害活性を有することから医薬品、医薬部外品、化粧品等の各種用途に使用することができる。[0001]
[Industrial application fields]
The present invention relates to a hyaluronidase inhibitor comprising a highly safe seaweed extract having excellent hyaluronidase inhibitory activity.
[0002]
[Prior art]
Hyaluronidase is a hydrolase of hyaluronic acid and is widely distributed in animal tissues as well as skin. Hyaluronic acid, which is a substrate for this enzyme, is a kind of mucopolysaccharide that is abundant in tissues such as skin, ligament, joint fluid, and vitreous body of the eye. For example, in the skin, cell protection, nutrient transport, tissue It plays an important role in maintaining moisture, maintaining flexibility, etc., and as synovial fluid in maintaining tissue structure, function and maintaining lubricity.
[0003]
The amount of living hyaluronic acid in skin and joints is known to decrease with aging or pathological conditions, resulting in dry skin, rough skin, firmness, reduced elasticity, increased spots, wrinkles, or joints Causes joint pain, etc. due to deterioration of wettability.
In such a state, the hyaluronidase inhibitor is considered to contribute to the maintenance of the amount of biological hyaluronic acid by suppressing the degradation of hyaluronic acid.
Recently, hyaluronic acid-containing cosmetics are applied to the skin and hyaluronic acid is injected into the joints. Hyaluronidase inhibitors are also used to stabilize these exogenous hyaluronic acids. Can be used.
[0004]
In addition, hyaluronidase is activated during inflammation, destroying the matrix of connective tissue, infiltrating the tissues of inflammatory cells, enhancing vascular permeability, and the process of histamine release from mast cells in type I allergy It is known that there is a high possibility of intervening in
Therefore, the hyaluronidase inhibitory activity is not only involved in maintaining the hyaluronic acid level in the living body, but also shows a high correlation with anti-inflammatory and anti-allergic activities. In fact, hyaluronidase inhibitory activity has been observed in many of the anti-inflammatory agents and antiallergic agents developed so far, such as indomethacin, aspirin, sodium cromoglycate, and tranilast.
[0005]
From the above, development of a hyaluronidase inhibitor having excellent hyaluronidase inhibitory activity and high safety when applied to the human body such as skin is expected.
[0006]
[Problems to be solved by the invention]
An object of the present invention is to provide a hyaluronidase inhibitor having excellent hyaluronidase inhibitory activity and excellent safety.
[0007]
[Means for Solving the Problems]
In order to solve the above-mentioned problems, the present inventors have studied various natural products, particularly plant extracts.
For land plants already, tea polyphenols extracted from tea for drinking (Japanese Patent Laid-Open No. 6-9391), extracts of chimpi, pheasant and rakan fruit used as herbal medicine or food and drink (Japanese Patent Laid-Open No. 6) No.-80576), Vulgaris extract which is a beech family plant (JP-A-6-239757), cashew nut shell oil (JP-A-6-329526), Urushiaceae plant extract (JP-A-7-10765), etc. Although substances having hyaluronidase inhibitory activity have been found, the present inventors conducted extensive screening to develop a new hyaluronidase inhibitor, and as a result, the following hyaluronidase inhibition was performed on the following seaweed extract. They found the activity and completed the present invention.
[0008]
That is, the hyaluronidase inhibitor of the present invention is a green algae of the genus Hanemo, Iwata, Mir, Brown algae Matsumo, Okinawa mozuku, Mozuku, Lessonia, Macrocystis, Hibamata, Davilia, Red algae It is characterized by containing as an active ingredient an extract of seaweeds belonging to the genus Amanori, Hiluxa, Obakusa, Funori, Suginori, Iridaae, Tsunogata, Darus and Igis.
[0009]
[Action]
Regarding the mechanism by which the seaweed extract of the present invention exhibits an excellent anti-aging effect on the skin and the like, the hyaluronidase inhibitory active substance contained in the extract suppresses the degradation of hyaluronic acid in skin cells, its level By maintaining the above, it is presumed that the skin moisturizing property, flexibility, and elasticity are prevented from being lowered and a remarkable skin aging preventing effect or the like is exhibited.
In addition, its superior hyaluronidase inhibitory activity is effective in preventing and treating inflammation and allergies caused by hyaluronidase.
[0010]
The contents of the present invention will be described in detail below.
Examples of the seaweed used in the present invention include, for example, the green algae of the genus Anemone (Bryopsis plumosa), the genus Iwata, the caulerpa lentillifera, the genus Mill (Codium fragile), the brown algae, the pine genus Matsumo. (Analipus japonicus), Okinawa mozuku (Cladosiphon okamuranus), Mozuku mosquito (Nemacystis decipiens), Lessonia genus Lessonia nigrescens, Macrocystis genus Giant kelp (Macrocystis pyrifera), Hibama cens uc ), Durvillea antarctica in the genus Davilia, red physae, Asperm (Porphyra tenera) in the genus Amanori, Porphyra yezoensis, Pterocladia tenuis in the genus Pterocladia tenuis, The mafnori (Gloiopel tis tenax), Gigartina chamissoi in the genus Suginori, Iridaea pulchra in the genus Iridaea, aka Iridaea cornucopiae, Chodrus crispus in the genus genus cc (Rhodymenia palmata), and the genus Igis can include amera (Ceramium boydenii).
[0011]
The method for extracting the substance of the present invention is not particularly limited, and a normal extraction method is adopted. The solvent is selected from the group consisting of water, hydrophilic organic solvents, other organic solvents and the like, or any two or more kinds of mixed solvents. Extracted from seaweed.
Examples of the organic solvent include methanol, ethanol, isopropanol, n-butanol, 1,3-butylene glycol, propylene glycol, ethyl acetate, acetone, methyl ethyl ketone, acetonitrile, dimethyl sulfoxide, dimethylformamide, chloroform, n-hexane, benzene and the like. Is mentioned.
Among these, it is particularly preferable to perform extraction using water or a mixture of water and a lower alcohol such as methanol, ethanol, or isopropanol. In this case, the ratio of water to lower alcohol is preferably 100/0 to 30/70 (V / V, volume ratio) of water / lower alcohol.
The ratio between the seaweed bulk and the extraction solvent is preferably such that the seaweed bulk (dry matter) / solvent ratio is 1/50 to 1/2.
As other extraction conditions, the extraction temperature is not particularly limited, but it is preferably performed in the range of 5 to 80 ° C. with stirring for 1 to 24 hours. The extraction pH is not particularly limited as long as it is not extremely acidic or extremely alkaline.
[0012]
This extract may be used as it is, or may be a diluted solution, a concentrated extract, a dry powder by freeze drying, or a paste.
When prepared as a dry powder, it is preferably used by dissolving in water or lower alcohol such as methanol, ethanol or isopropanol containing water in advance, or solubilizing in a composition for external use containing water described below. .
[0013]
Examples of the dosage form of the hyaluronidase inhibitor of the present invention include tablets, capsules, powders, oral liquids, fine granules and the like, and liniments, sprays, lotions, ointments and the like. Can be used for the outer skin.
When used as a skin external preparation, the seaweed extract, which is an essential component, can be blended at an arbitrary concentration, but usually 0.01 to 30% by weight (hereinafter simply referred to as “%”) in various skin external preparations. Preferably, 0.1 to 10% is added.
[0014]
In addition to the above essential components, the external preparation for skin containing the seaweed extract, which is an essential component of the present invention, is a raw material usually used for external preparations, for example, surfactants, oils, alcohols, humectants, thickening agents. Additives, preservatives, antioxidants, chelating agents, pH adjusters, fragrances, pigments, UV absorbers / scatterers, vitamins, amino acids, water, and the like can be added.
[0015]
Specifically, as the surfactant, lipophilic glycerin monostearate, self-emulsifying glycerin monostearate, polyglycerin monostearate, sorbitan monooleate, polyethylene glycol monostearate, polyoxyethylene sorbitan monooleate, Nonionic surfactants such as polyoxyethylene cetyl ether, polyoxyethylenated sterol, polyoxyethylenated lanolin, polyoxyethylenated beeswax, polyoxyethylene hydrogenated castor oil, sodium stearate, potassium palmitate, sodium cetyl sulfate, Anionic surfactants such as sodium lauryl phosphate, triethanolamine palmitate, sodium polyoxyethylene lauryl phosphate, sodium N-acyl glutamate, stearyl chloride Le benzyl ammonium cationic surfactants such as stearyltrimethylammonium chloride, may be exemplified hydrochloric alkylamino ethyl glycine solution, amphoteric surfactants such as lecithin.
[0016]
Oils include castor oil, olive oil, cacao oil, coconut oil, palm oil, tree wax, jojoba oil, grape seed oil, avocado oil and other animal oils such as mink oil and egg yolk oil, beeswax, whale Waxes such as wax, lanolin, carnauba wax and candelilla wax, hydrocarbons such as liquid paraffin, squalane, microcrystalline wax, ceresin wax, paraffin wax, petrolatum, lauric acid, myristic acid, stearic acid, oleic acid, isostearic acid Natural and synthetic fatty acids such as behenic acid, natural and synthetic higher alcohols such as cetanol, stearyl alcohol, hexyl decanol, octyldodecanol, lauryl alcohol, isopropyl myristate, isopropyl palmitate, octyldodecyl myristate, In octyldodecyl, it can be exemplified esters of cholesterol oleate, etc. and the like.
[0017]
Examples of humectants include polyhydric alcohols such as glycerin, propylene glycol, 1,3-butylene glycol, sorbitol, polyglycerin, polyethylene glycol and dipropylene glycol, amino acids, NMF components such as sodium lactate and sodium pyrrolidonecarboxylate, and hyaluron. Examples thereof include water-soluble polymer substances such as acid, collagen, mucopolysaccharide, and chondroitin sulfate.
[0018]
Thickeners include natural polymeric substances such as sodium alginate, xanthan gum, aluminum oxalate, quince seed extract, tragacanth gum, starch, semi-synthetic polymers such as methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, soluble starch, and cationized cellulose. Examples include materials, synthetic polymer materials such as carboxyvinyl polymer and polyvinyl alcohol.
[0019]
Examples of preservatives include benzoate, salicylate, sorbate, dehydroacetate, p-hydroxybenzoate, 2,4,4′-trichloro-2′-hydroxydiphenyl ether, 3,4,4′-trichlorocarbani Lido, benzalkonium chloride, hinokitiol, resorcin, ethanol and the like can be exemplified.
[0020]
Dibutylhydroxytoluene, butylhydroxyanisole, propyl gallate, ascorbic acid, etc. as antioxidants, and disodium edetate, ethylenediaminetetraacetate, pyrophosphate, hexametaphosphate, citric acid, tartaric acid as chelating agents Examples of pH adjusters such as gluconic acid include sodium hydroxide, triethanolamine, citric acid, sodium citrate, boric acid, borax, and potassium hydrogen phosphate.
[0021]
Examples of the ultraviolet absorbing / scattering agent include 2-hydroxy-4-methoxybenzophenone, octyldimethylparaaminobenzoate, ethylhexylparamethoxycynamate, titanium oxide, kaolin, talc and the like.
As vitamins, vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin F, vitamin K, vitamin P, vitamin U, carnitine, ferulic acid, γ-oryzanol, α-lipoic acid, orotic acid and the like And derivatives thereof.
As amino acids, glycine, alanine, valine, leucine, isoleucine, serine, threonine, phenylalanine, tyrosine, tryptophan, cystine, cysteine, methionine, proline, hydroxyproline, aspartic acid, glutamic acid, arginine, histidine, lysine and their derivatives Etc. can be illustrated.
[0022]
The optional component is not limited to these. By appropriately blending the above essential components and optional components, for example, the seaweed extract of the present invention 0.01 to 30%, oil components 0 to 80%, surfactants 0 to 12%, moisturizer 1 to An external preparation for skin containing 15%, purified water balance, and a small amount of antiseptic can be provided. Specifically, it can be used as a product form such as cream, milky lotion, skin lotion, cosmetic liquid, pack agent, under make-up, foundation, jelly agent, ointment and the like.
[0023]
Specific examples in the case of using the hyaluronidase inhibitor of the present invention as a skin cosmetic are as follows (1) to (4).
(1) In the case of skin cream, the seaweed extract of the present invention 0.1 to 10%, oil 20 to 70%, surfactant 2 to 7%, moisturizer 1 to 10%, purified water balance, preservative trace amount, Skin cream containing a small amount of fragrance.
[0024]
(2) In the case of emulsion, the seaweed extract of the present invention 0.1 to 10%, oil 10 to 40%, alcohols 0 to 15%, surfactant 1 to 5%, humectant 1 to 10%, thickener An emulsion containing 0-2%, purified water balance, preservative traces, fragrance traces.
[0025]
(3) In the case of lotion and serum, the seaweed extract of the present invention 0.1 to 10%, alcohols 5 to 20%, surfactant 0 to 2%, moisturizer 2 to 8%, thickener 0 to Contains 2%, antioxidant 0-0.5%, chelating agent 0-0.1%, pH adjuster 0-0.2%, purified water balance, preservative trace, dye 0 trace, fragrance trace. Lotion, essence.
[0026]
(4) In the case of a pack agent The seaweed extract 0.1 to 10% of the present invention, alcohols 2 to 10%, humectant 2 to 10%, inorganic powder 0 to 20%, film forming agent 10 to 20%, Packing agent containing purified water balance, preservatives and fragrances.
[0027]
【Example】
Next, the present invention will be specifically described with reference to examples and test examples, but the present invention is not limited to the following examples.
[0028]
Production example (production of seaweed extract)
100 g of dried matsumo was stirred with 20 times the amount of water for 3 hours, and the supernatant was concentrated and freeze-dried to obtain 16 g of matsumo extract. Similarly, seaweeds other than pineapples, namely, green alga honey, squirrels, mills, jujusmo, brown alga Okinawa, mozuku, Ecklonia maxima, giant kelp, Lessonia nigrescens, hibermata, Durvillea antarctica, red moss, red algae Extracts were obtained for each of Ogonori, Asakusanori, Susbinori, Hiraksa, Pterocladia tenuis, Ochlochori, Makhnori, Gigartina chamissoi, Iridaea pulchra, Ezotsunomata, Tochaka, Tsunomata, Durus, Kaginori and Amica.
In addition, other solvents such as methanol, ethanol, isopropanol, n-butanol, 1,3-butylene glycol, propylene glycol, ethyl acetate, acetone, methyl ethyl ketone, acetonitrile, dimethyl sulfoxide, dimethylformamide, chloroform, n-hexane, benzene Also for the above, extracts were obtained from the respective seaweeds in the same manner as the above water.
[0029]
Test Example 1 (hyaluronidase inhibitory activity test)
The hyaluronidase inhibitory activity of each seaweed extract (extract sample) obtained in the above production example was measured by the following method.
200 μl of each seaweed extract sample obtained in the above production example was added to 100 μl (1,580 units / ml) of an enzyme (type IV-S from Bovine testis, manufactured by SIGMA) solution, and the mixture was allowed to stand at 37 ° C. for 20 minutes. Next, 200 μl of enzyme activator (Compound 48/80, manufactured by SIGMA) solution (0.1 mg / ml) was added and allowed to stand at 37 ° C. for 20 minutes, and then the substrate was potassium hyaluronate (from rooster comb, Jun Wako). 500 μl of solution (0.4 mg / ml) was added and left at 37 ° C. for 40 minutes.
Next, 200 μl of 0.4N sodium hydroxide solution was added to stop the reaction, and the amount of N-acetylhexosamine produced by a modification of the Morgan-Elson method (J. Biol. Chem., 217, 959 (1955)) was measured as the absorbance. Obtained from OD 585 nm.
In addition, 0.1 mM acetic acid buffer (pH 3.5) was used for the enzyme reaction, and the hyaluronidase inhibitory activity was calculated by the inhibition rate obtained from the following formula.
[0030]
[Expression 1]
[0031]
Table 1 below shows the results of calculating the 50% inhibition concentration (IC 50 ) from the inhibition rates at various sample concentrations for each seaweed water extract (extract sample) obtained in the above production example. It shows that hyaluronidase inhibitory activity is so high that a numerical value is low.
[0032]
[Table 1]
[0033]
(Consideration of Table 1)
As is clear from the results shown in Table 1 above, the seaweed extract of the present invention, that is, the green alga honey, scallop, mill, brown algae pine, Okinawa mozuku, mozuku, Ecklonia maxima, giant kelp, Lessonia nigrescens, hibamata , Durvillea antarctica, red alga Asakusa Nori, Susabi Nori, Hiraksa, Pterocladia tenuis, Fukurofunori, Mafunori, Gigartina chamissoi, Iridaea pulchra, Ezotsuno Mata, Tochaka, Tsunogata, Darus, Amyxa Many of them showed very high hyaluronidase inhibitory activity comparable to sodium acid (control). In addition, the extracts obtained from other extraction solvents showed almost the same results as the water extract.
In particular, Lessonia nigrescens belonging to the genus Lessonia, Durvillea antarctica belonging to the genus Davilia, Mafunori belonging to the genus Funori, Iridaea pulchra belonging to the genus Iridaea, and Ezotsunomata were found to have extremely high hyaluronidase inhibitory activity.
In contrast, even for the same seaweed extract, the seaweed extract that is outside the scope of the present invention, i.e., the green alga Jujumo sp., The brown algae Shiomidomo, the red alga Ogonori, Each extract of the genus Kaginori showed no hyaluronidase inhibitory activity.
[0034]
Example 1, Comparative Example 1 (Production of cream)
Components 1 to 7 and 8 to 11 shown in Table 2 below were separately mixed and dissolved, and then the components 1 to 7 solution was added and emulsified while stirring the components 8 to 11, and then cooled. While adding the component 12, the solution was cooled to room temperature, and creams shown in Table 2 below were prepared.
In addition, the number in a table | surface shows compounding quantity (weight%) and POE (20) shows polyoxyethylene and its addition mole number (same also in a following example etc.). Moreover, the comparative example 1 is a case where a cream is prepared without blending the seaweed extract of the present invention as component 8 (also prepared without blending the seaweed extract in the following comparative examples 2 to 4). .
[0035]
[Table 2]
[0036]
Example 2, Comparative Example 2 (Manufacture of lotion)
Components 1 to 6 shown in Table 3 below were sequentially added to component 7 and dissolved, and further component 8 was added to prepare a lotion shown in Table 3 below.
[0037]
[Table 3]
[0038]
Example 3 and Comparative Example 3 (Manufacture of serum)
Components 1 to 4 and components 5 to 9 shown in Table 4 below were separately dissolved and then mixed to prepare a cosmetic liquid.
[0039]
[Table 4]
[0040]
Example 4, Comparative Example 4 (production of emulsion)
Components 1 to 7 shown in Table 5 below were dissolved by heating at 70 ° C. On the other hand, components 8 to 13 were heated and dissolved at 70 ° C., and the oil solution (components 1 to 7) was added and emulsified. Then, while cooling, component 14 was added on the way and cooled to room temperature. The emulsion shown in 5 was prepared.
[0041]
[Table 5]
[0042]
Test example 2 (use test evaluation result)
The effectiveness of the creams, lotions, serums, and emulsions of Examples 1 to 4 and Comparative Examples 1 to 4 including the water extract of each seaweed obtained in the above production example was evaluated by the following use test.
(Use test)
Five women (30 to 50 years old) are allowed to use Examples 1 to 4 and Comparative Examples 1 to 4 separately for the left and right faces twice a day (morning and evening) for 3 consecutive months for half a face. After that, a questionnaire survey was conducted on the small wrinkles (A) and the quality [gloss (B), moisture (C)].
Questionnaire surveys are: ○ (with improvement effect) when the example (invention product) is good, △ when the example (invention product) and the comparative example are not different, and × (when the comparison example is good) No improvement effect).
The results of these use tests are shown in Table 6 below.
[0043]
[Table 6]
[0044]
(Consideration of Table 6)
As is apparent from the results shown in Table 6 above, preparations (Examples) [creams, lotions, serums, emulsions] containing the extract of seaweed within the scope of the present invention are small wrinkles (A) and glosses (B). The improvement effect of moisture (C) was recognized. This effect is because the hyaluronidase inhibitory active substance contained in the seaweed extract suppresses the degradation of hyaluronic acid in skin cells and maintains its level, thereby suppressing the decrease in skin moisture retention, flexibility, elasticity, It is presumed that remarkable skin cell activation and skin aging preventive effects, etc., prevent wrinkles and rough skin, and give a smooth, moist and youthful skin.
On the other hand, even in the same seaweed extract, the seaweed extract that is outside the scope of the present invention, that is, the green alga Jujumo sp., The brown algae Shiomidro genus, the red algae Ogonori genus, Kagonori genus The preparation (comparative example) [cream, lotion, cosmetic liquid, milky lotion] containing each extract of Kaginori showed no improvement effect in any of small wrinkles (A), gloss (B), and moisture (C).
[0045]
【The invention's effect】
According to the present invention, the hyaluronic acid decomposition inhibitory action can activate skin cells and prevent skin aging, prevent the occurrence of wrinkles and rough skin, and provide an effect of giving a smooth, moist and youthful skin. By blending this, a hyaluronidase inhibitor suitable for a highly safe external preparation for skin and the like is provided.
The hyaluronidase inhibitor of the present invention maintains joint wettability and can be used as a therapeutic agent for joints, and is also useful as an anti-inflammatory and anti-allergic agent.
Furthermore, since the hyaluronidase inhibitor of the present invention is extracted from seaweed that has been used for food since ancient times, it is extremely safe to human body, and has excellent hyaluronidase inhibitory activity, It can be used for various applications such as quasi drugs and cosmetics.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15446896A JP3807782B2 (en) | 1995-06-22 | 1996-06-14 | Hyaluronidase inhibitor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15644895 | 1995-06-22 | ||
JP7-156448 | 1995-06-22 | ||
JP15446896A JP3807782B2 (en) | 1995-06-22 | 1996-06-14 | Hyaluronidase inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0967266A JPH0967266A (en) | 1997-03-11 |
JP3807782B2 true JP3807782B2 (en) | 2006-08-09 |
Family
ID=26482737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP15446896A Expired - Lifetime JP3807782B2 (en) | 1995-06-22 | 1996-06-14 | Hyaluronidase inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3807782B2 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000351722A (en) * | 1999-06-07 | 2000-12-19 | Tekunooburu:Kk | Skin cosmetic |
JP2002104952A (en) * | 2000-09-28 | 2002-04-10 | Noevir Co Ltd | External preparation for skin |
KR100419134B1 (en) * | 2000-10-16 | 2004-02-14 | 엔프라니 주식회사 | Cosmetic material containing Padina Pavonica extract |
JP2002308791A (en) * | 2001-04-11 | 2002-10-23 | Pias Arise Kk | Ceramidase activity inhibitor, skin care preparation containing the activity inhibitor, cosmetic, and quasi-drug |
WO2003041679A2 (en) * | 2001-11-14 | 2003-05-22 | Larena | Product containing a red alga extract of the genus porphyra and uses thereof for protecting cells |
JP2003238384A (en) * | 2002-02-14 | 2003-08-27 | Fancl Corp | External preparation for skin |
JP2003267852A (en) * | 2002-03-14 | 2003-09-25 | Noevir Co Ltd | Cell activator |
FR2838341B1 (en) * | 2002-04-10 | 2007-07-27 | Gelyma | MARINE ALGAE EXTRACT OF THE GENUS CYSTOSEIRA AND USE IN CARE PRODUCTS |
JP2004002217A (en) * | 2002-05-31 | 2004-01-08 | Noevir Co Ltd | External preparation for skin |
JP5008813B2 (en) * | 2002-10-30 | 2012-08-22 | 沖縄県 | Anti-Skin Cancer Agent Containing Cubileta Extract |
FR2858771B1 (en) * | 2003-08-14 | 2005-10-28 | Daniel Jouvance Rech S Et Crea | ASSOCIATION OF ACTIVE AGENTS EXTRACTED FROM ALGAE AND COSMETIC COMPOSITIONS COMPRISING SAID ASSOCIATION |
JP4540967B2 (en) * | 2003-11-07 | 2010-09-08 | 日本メナード化粧品株式会社 | NMF production promoter |
US7025966B2 (en) | 2003-12-05 | 2006-04-11 | Mary Kay Inc. | Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin |
JP5058447B2 (en) * | 2005-02-28 | 2012-10-24 | 株式会社桃屋 | Antioxidant containing human exothera green algae extract as active ingredient |
JP4734648B2 (en) * | 2006-08-21 | 2011-07-27 | 国立大学法人 琉球大学 | Hyaluronidase inhibitor or therapeutic agent for atopic dermatitis derived from Okinawa mozuku |
KR101531415B1 (en) * | 2006-10-17 | 2015-06-24 | 바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스 | Use of FGF-2 or FGF-Beta Growth Factor Protecting Substance |
JP5147218B2 (en) * | 2006-11-13 | 2013-02-20 | ハイドロックス株式会社 | Seaweed-derived immunostimulant and anti-inflammatory agent |
EP2116224B1 (en) * | 2006-11-27 | 2016-01-27 | JNC Corporation | Cosmetic composition |
JP2008239493A (en) * | 2007-03-23 | 2008-10-09 | Naris Cosmetics Co Ltd | External preparation for skin |
JP2008291004A (en) * | 2007-04-26 | 2008-12-04 | Oriza Yuka Kk | Composition for beautiful skin |
JP5661994B2 (en) * | 2008-01-04 | 2015-01-28 | クラシエ製薬株式会社 | Composition or internal preparation with anti-stress / fatigue prevention, skin texture improvement or wrinkle improvement / prevention effect |
JP2009294200A (en) * | 2008-05-09 | 2009-12-17 | Pola Chem Ind Inc | Differentiation method for tight junction function restoring agent |
JP2009294202A (en) * | 2008-05-09 | 2009-12-17 | Pola Chem Ind Inc | Differentiation method for involvement of tight junction in material transport |
KR101102829B1 (en) * | 2008-09-12 | 2012-01-05 | 재단법인 제주테크노파크 | Perilla extract and its use as anti-inflammatory |
KR100937781B1 (en) * | 2008-09-18 | 2010-01-20 | 화성용 | Preventing liver injury and improving liver function effects of ena-actimineral resources |
JP2011012052A (en) * | 2009-06-01 | 2011-01-20 | Sonoe Shimada | Antiinflammatory composition containing seaweed extract as active ingredient |
US9603881B2 (en) * | 2009-11-11 | 2017-03-28 | Isp Investments Llc | Bioactive fractions from stress-induced photosynthetic organisms and methods of their manufacture and use |
KR101839013B1 (en) * | 2010-11-25 | 2018-03-15 | (주)아모레퍼시픽 | Cosmetic composition containing SARGASSUM FULVELLUM extract, CODIUM FRAGILE extract and UNDARIA PINNATIFIDA extract |
JP2012121865A (en) * | 2010-12-10 | 2012-06-28 | Kyoei Kagaku Kogyo Kk | Skin lightening cosmetic |
IT1404145B1 (en) * | 2010-12-27 | 2013-11-15 | Altergon Sa | COMPOSITIONS OF HYALURONIC ACID STABILIZED TOWARDS THE DEGRADATION OF HEAT OR ENZYMES |
JP6050573B2 (en) * | 2011-08-10 | 2016-12-21 | ロート製薬株式会社 | LTBP-4 production promoter |
JP2016135769A (en) * | 2015-01-14 | 2016-07-28 | 御木本製薬株式会社 | Claudin production-promoting agent, occludin production-promoting agent, and tight junction function-enhancing agent |
JP6242849B2 (en) * | 2015-01-14 | 2017-12-06 | 御木本製薬株式会社 | Kallikrein-related peptidase production promoter, LEKTI production promoter, SLPI production promoter, keratinization normalizing agent, corneodesmosome degradation normalizing agent |
JP2017132761A (en) * | 2016-01-25 | 2017-08-03 | 御木本製薬株式会社 | Psoriasin production promoter |
KR102153355B1 (en) * | 2019-02-12 | 2020-09-08 | 제주대학교 산학협력단 | A composition comprising Caulerpa racemosa extracts or fraction having anti-oxidation or anti-inflammation activity |
KR102289551B1 (en) | 2019-07-17 | 2021-08-13 | 주식회사 제이투케이바이오 | A skin-care agent containing hyaluronic acid complex |
-
1996
- 1996-06-14 JP JP15446896A patent/JP3807782B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH0967266A (en) | 1997-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3807782B2 (en) | Hyaluronidase inhibitor | |
JP4880816B2 (en) | Skin anti-aging agent | |
JP3483988B2 (en) | Skin preparation | |
EP2370052B1 (en) | Novel sebum secretion inhibitory agent | |
JPH1121247A (en) | Skin activator and allergy inhibitor | |
JP5530657B2 (en) | Hyaluronic acid enhancer in skin, and topical skin preparation and cosmetic containing the hyaluronic acid enhancer in skin | |
JP2003238432A (en) | Hyaluronic acid accumulation promoter | |
KR101763373B1 (en) | Cosmetic composition comprising plant extracts as effective component | |
JP2005008539A (en) | Matrix metalloproteinase inhibitor | |
JPH07101871A (en) | Promoter for synthesis of hyaluronic acid in living body | |
JP3122167B2 (en) | Artemisia extract and use thereof | |
JP4796734B2 (en) | Matrix metalloprotease activity inhibitor | |
JP2000247829A (en) | Cosmetic, unregulated drug, medicine and food | |
EP1285661B1 (en) | Use of an antioxidant comprising an extract of mozuku | |
JP4583655B2 (en) | Anti-allergic skin external composition | |
EP0531978A2 (en) | Promotor for biological hyaluronic acid synthesis, composition externally applied to the skin and use thereof | |
KR20070043449A (en) | Nanoemulsion skin anti-aging cosmetic composition | |
JP3172753B2 (en) | Biological hyaluronic acid synthesis promoter | |
WO2007135841A1 (en) | Cosmetic preparation containing dimer dilinoleic acid diethylene glycol oligomer ester | |
JPH0987188A (en) | Skin preparation for external use and bathing agent | |
JPH05306214A (en) | Cosmetic | |
JP3235922B2 (en) | Cosmetics | |
JP2001233755A (en) | Skin external preparation composition | |
JP4828077B2 (en) | Topical skin preparation | |
JP3784442B2 (en) | Topical skin preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050208 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050411 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060307 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060317 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060516 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060516 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090526 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100526 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110526 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130526 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130526 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140526 Year of fee payment: 8 |
|
EXPY | Cancellation because of completion of term |